ChemoMetec’s Annual Report Reflects Resilience
Despite facing a challenging year, ChemoMetec is navigating its market with resolve and tactical insight. The annual report for the 2023/24 financial year indicates a decrease in revenue but highlights strong plans aimed at recovery and growth.
Overview of Revenue and Profit
This year, ChemoMetec experienced a revenue decline of 8% year-over-year, totaling DKK 407.4 million. This decrease mainly stemmed from a substantial 35% drop in instrument sales. However, sales from consumables and services saw a positive increase of 13%, reflecting a shift in customer buying habits during these uncertain times.
Insights from the CEO on Future Growth
Martin Helbo Behrens, the CEO of ChemoMetec, provided insights into the company’s strategic path forward. He stated, “Market conditions have been tough, but we're shifting our focus back to a more commercial strategy. The upcoming launches of our advanced XcytoMatic instruments are promising signs of restoration.”
Strategic Product Launches Planned
As part of their recovery strategy, ChemoMetec is preparing to expand the launch of their new XcytoMatic 40 and XcytoMatic 30 instruments. These products are not merely new items; they play a crucial role in enhancing ChemoMetec's overall product range. Through these advancements, ChemoMetec aims to provide greater support to customers across their value chains, from development to production.
Financial Performance Metrics Analysis
This year's operating profit (EBITDA) stood at DKK 186.2 million, a significant decline from DKK 251 million the previous year. The EBITDA margin dropped from 57% to 46%, affected by increased staffing costs and a rise in the cost of goods sold.
Dividends and Looking Ahead
The Board of Directors has proposed a dividend distribution of DKK 4.0 per share, totaling DKK 69.6 million, which reflects a commitment to delivering shareholder value despite lower earnings. Moving forward, the forecast for the 2024/25 financial year suggests expected revenues of DKK 435-450 million, along with an EBITDA prediction ranging from DKK 216-223 million. This outlook brings a sense of optimism for stakeholders.
Commitment to Research and Development
ChemoMetec is dedicated to continuing investments in research and development, ensuring its instruments stay at the cutting edge of technology. By actively responding to industry trends and fulfilling customer needs, ChemoMetec aims not only to regain lost ground but also to explore new markets and opportunities.
Contact Information
For further information, interested individuals can contact:
Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20
About ChemoMetec
Established in 1997 and listed on Nasdaq OMX Copenhagen, ChemoMetec is well-known for its innovative instruments for cell counting and various measurement technologies. The company serves the pharmaceuticals, biotech, and agricultural sectors, maintaining partnerships with some of the most influential players in these industries.
Frequently Asked Questions
What is the main focus of ChemoMetec's annual report?
The report highlights the company's revenue decline, shifts in strategic product launches, and anticipation for future growth.
How has ChemoMetec's revenue changed in the past year?
The company saw an 8% drop in revenue, bringing it down to DKK 407.4 million, largely due to declining instrument sales.
What new products are being launched by ChemoMetec?
ChemoMetec is set to launch the XcytoMatic 40 and 30 instruments to enhance its product lineup.
What is the forecast for ChemoMetec in the upcoming year?
For the 2024/25 fiscal year, ChemoMetec expects revenue between DKK 435-450 million and an EBITDA of DKK 216-223 million.
What steps is ChemoMetec taking to improve its financial performance?
The company is focusing on its commercial strategy, launching new products, and diversifying its services to strengthen its market position.
